Why the study?
Does prophylactic low-molecular weight heparin prevent symptomatic VTEs in ambulatory patients with advanced pancreatic cancer?
Does prophylactic low-molecular weight heparin prevent symptomatic VTEs in ambulatory patients with advanced pancreatic cancer?
Prophylactic low-molecular weight heparin is highly efficacious and feasible for preventing symptomatic VTEs in ambulatory patients with advanced pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Supports prophylactic enoxaparin in advanced pancreatic cancer outpatients; challenges prior low-certainty evidence against benefit.
Pelzer et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: